Skip to main content
placeholder image

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Journal Article


Abstract


Publication Date


  • 2022

Citation


  • Janne, P. A., Wang, M., Camidge, D. R., Mitchell, P., Fang, J., Nian, W., . . . Yang, J. C. -H. (2022). Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. Journal of Clinical Oncology, 40(16_suppl), 9015. doi:10.1200/jco.2022.40.16_suppl.9015

Web Of Science Accession Number


Start Page


  • 9015

End Page


  • 9015

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication


Abstract


Publication Date


  • 2022

Citation


  • Janne, P. A., Wang, M., Camidge, D. R., Mitchell, P., Fang, J., Nian, W., . . . Yang, J. C. -H. (2022). Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.. Journal of Clinical Oncology, 40(16_suppl), 9015. doi:10.1200/jco.2022.40.16_suppl.9015

Web Of Science Accession Number


Start Page


  • 9015

End Page


  • 9015

Volume


  • 40

Issue


  • 16_suppl

Place Of Publication